Barenbrock M, Spieker C, Rahn K H, Zidek W
Medizinische Poliklinik, Westfälischen Wilhelms-Universität, Münster, Germany.
Clin Nephrol. 1993 Oct;40(4):241-3.
Hypertension is a major complication in kidney transplantation and contributes to the high cardiovascular mortality of renal transplanted recipients. The aim of the present study was to evaluate the therapeutic effect of phlebotomy on blood pressure in posttransplant hypertension associated with erythrocytosis. In 12 renal transplanted patients (7 male, 5 female, aged 29-52 years) with erythrocytosis (defined by hematocrit > 52% or hemoglobin > 170 g/l), a 24-hour-monitoring of blood-pressure and heart rate (SpaceLabs SL90207) was performed before, 2 and 6 weeks after phlebotomy. Patients with iron-deficiency and/or transplant rejection were excluded from the study. Ten of 12 patients were on antihypertensive treatment before phlebotomy. Phlebotomy (500 ml) was repeated three times on average within the first two weeks, until hematocrit decreased below 45%. The phlebotomy therapy lowered the hematocrit after two weeks from 54.8 +/- 2.8% to 44.3 +/- 4.2% and 43.0 +/- 5.6% after six weeks. Before phlebotomy, the blood pressure was systolic 153.2 +/- 15.1 mmHg and diastolic 95.2 +/- 9.5 mmHg. After repeated phlebotomy, there was a significant decrease of blood pressure to systolic 139.0 +/- 14.1 and diastolic 85.3 +/- 8.2 mmHg (p < 0.01). Without change of hematocrit and hemoglobin, there was no further change of blood pressure after six weeks (systolic 140.1 +/- 9.9 mmHg, diastolic 86.3 +/- 9.5 mmHg). The heart rate did not change significantly during the therapy. The antihypertensive treatment could be reduced in most of the patients. The present study demonstrates the therapeutic effect of phlebotomy in posttransplant hypertension associated with erythrocytosis.(ABSTRACT TRUNCATED AT 250 WORDS)
高血压是肾移植的主要并发症,也是导致肾移植受者心血管死亡率高的原因。本研究旨在评估放血疗法对肾移植后红细胞增多症相关高血压患者血压的治疗效果。对12例肾移植后红细胞增多症患者(7例男性,5例女性,年龄29 - 52岁,红细胞增多症定义为血细胞比容>52%或血红蛋白>170g/l)在放血前、放血后2周和6周进行24小时血压和心率监测(SpaceLabs SL90207)。缺铁和/或移植排斥患者被排除在研究之外。12例患者中有10例在放血前接受抗高血压治疗。放血(500ml)在前两周平均重复3次,直至血细胞比容降至45%以下。放血疗法使血细胞比容在两周后从54.8±2.8%降至44.3±4.2%,六周后降至43.0±5.6%。放血前,血压收缩压为153.2±15.1mmHg,舒张压为95.2±9.5mmHg。反复放血后,血压显著下降至收缩压139.0±14.1mmHg,舒张压85.3±8.2mmHg(p<0.01)。在血细胞比容和血红蛋白无变化的情况下,六周后血压无进一步变化(收缩压140.1±9.9mmHg,舒张压86.3±9.5mmHg)。治疗期间心率无显著变化。大多数患者的抗高血压治疗可以减少。本研究证明了放血疗法对肾移植后红细胞增多症相关高血压的治疗效果。(摘要截选至250字)